Development Stage
Program (Target)
Indication
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Program
LM11A-31 (p75NTR)
Indication: Alzheimer's Disease
Phase 2a completed1
Indication: Progressive Supranuclear Palsy
Starting 2H 2026
Indication: HIV Dementia
Starting 2H 2026
Indication: Rare Neuro Indication
In Evaluation
Program
PTX-4-3 (TrkB)
Indication: Neurodegeneration
Program
PTX-10-3 (TrkB/C)
Indication: Neurodegeneration
1 Shanks et al. p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial. Nat Med 30, 1761–1770 (2024)